Lakshmi Nayak, MD

Dr. Motoo Nagane discusses the evolving treatment pathway for primary CNS lymphoma (PCNSL) in Japan following the approval of tirabrutinib for relapsed or refractory disease.

Dr. Chieh-Lung Cheng describes the impact of tirabrutinib availability on the management of relapsed/refractory primary CNS lymphoma (PCNSL) in Taiwan.

Dr. Christian Grommes discusses the emerging role of BTK inhibitors in relapsed/refractory primary CNS lymphoma (PCNSL), focusing on U.S. off-label use and ongoing clinical investigation.

Experts unpack BTK inhibitor use for relapsed primary CNS lymphoma, sharing Japan and Taiwan real‑world data, trials, and tirabrutinib insights.

Experts debate BTK inhibitors for primary CNS lymphoma, sharing trial and real-world insights on tirabrutinib and options for relapsed disease.

Lakshmi Nayak, MD, discusses phase 2 efficacy and safety data with tirabrutinib in relapsed/refractory primary and secondary CNS lymphoma.

Dr. Lakshmi Nayak presents results from the Phase II PROSPECT study, demonstrating that tirabrutinib monotherapy yields a 66.7% overall response rate and a manageable safety profile in patients with relapsed or refractory primary central nervous system lymphoma, supporting its potential as an effective treatment option in this challenging population.

Lakshmi Nayak, MD, discusses the mechanism of action of emavusertib and the study of this drug relapsed/refractory primary and secondary CNS lymphoma.

Lakshmi Nayak, MD, discusses the investigation of axi-cel in patients with relapsed/refractory primary and secondary CNS lymphoma.

Lakshimi Nayak, MD, discusses the diagnosis of patients with primary CNS lymphoma.

Primary central nervous system lymphoma is a rare and aggressive variant of extranodal non-Hodgkin lymphoma that occurs in the brain, spinal cord, cerebrospinal fluid, or eyes in the absence of systemic disease.